<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342054</url>
  </required_header>
  <id_info>
    <org_study_id>SINFRA_PROST</org_study_id>
    <nct_id>NCT02342054</nct_id>
  </id_info>
  <brief_title>Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer</brief_title>
  <acronym>SINFRA_PROST</acronym>
  <official_title>Prospective Phase II Trial of Single Fraction Real-time High-Dose-Rate (19-HDR) Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Cruces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more&#xD;
      advantageous than LDR-BT and External Beam Radiotherapy (EBRT), to the patient himself, and&#xD;
      in terms of resource allocation. Studies of HDR-BT monotherapy have encouraging results in&#xD;
      terms of biochemical control, patient survival and toxicity, but there are still certain&#xD;
      limitations that preclude recommending HDR-BT monotherapy outside the setting of a clinical&#xD;
      trial.&#xD;
&#xD;
      The primary endpoint of this study is to evaluate the safety, tolerance and impact on quality&#xD;
      of life (QoL) of the BT-HDR 19Gy administered in single fraction in patients with low and&#xD;
      intermediate risk prostate cancer. Secondary endpoint is to measure the efficacy, in terms of&#xD;
      cancer control and satisfaction of the patients undergoing the experimental treatment.&#xD;
&#xD;
      Forty nine patients will be recruited for the experimental procedure Quality of Life,&#xD;
      tolerance, gastrointestinal and genitourinary toxicity will be assessed using standardized&#xD;
      procedures and scales. Patient satisfaction with the procedure will be appraised using&#xD;
      five-category predetermined Likert scale questions.&#xD;
&#xD;
      Two different types of intermediate analyses will be performed: with 15 and 30 recruited&#xD;
      patients.&#xD;
&#xD;
      The experimental treatment tested in this study is very innovative. Since prostate cancer is&#xD;
      the most frequent cancer in men in Spain, this trial results are very likely to have a major&#xD;
      impact on the standard therapy for prostate cancer in our National Health Service, allowing&#xD;
      for a higher number of Hospitals within our country and other countries starting protocols of&#xD;
      HDR BT 19Gy in single fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment:&#xD;
&#xD;
      The patientÂ´s treatment will consist of MRI-TRUS fusion single HDR brachytherapy fraction (1&#xD;
      fraction of 1900 cGray).&#xD;
&#xD;
      Brachytherapy performed under general anesthesia as an outpatient procedure&#xD;
&#xD;
      TRUS-MRI fusion:&#xD;
&#xD;
      T2 axial volumetric sequence (VISTA) is imported directly from the picture archiving and&#xD;
      communication systems (PACS). Then MR images are reconstructed and segmented. Target volumes&#xD;
      (prostate gland, dominant intraprostatic lesions (DILs) Organs at risk (OARs) urethra and&#xD;
      rectum are delineated.&#xD;
&#xD;
      A transrectal sagittal volumetric ultrasound image is immediately acquired every 2 degrees, a&#xD;
      rapid reconstruction algorithm converts the series of 2D images into a 3D volume, which is&#xD;
      then displayed in axial, sagittal and coronal views and transferred to the module of fusion&#xD;
      with the MRI.&#xD;
&#xD;
      The MRI images and the real-time sonography examination are displayed on a split-screen with&#xD;
      the possibility of overlaying the images live in one image. A graphical user interface is&#xD;
      used for rigid manual registration of the ultrasound and MRI volumes. This interface allows&#xD;
      for displacements in the three dimensions and rotations, until both images are correctly&#xD;
      superimposed.&#xD;
&#xD;
      Then the contoured structures are transferred to the US dataset, and these contours are&#xD;
      slightly modified until a perfect matching with the US images is achieved.&#xD;
&#xD;
      Dose prescription:&#xD;
&#xD;
      Ultrasound images with the catheters in place will be exported to Oncentra Prostate. The&#xD;
      prostate, Foley catheter and anterior rectal wall will be contoured. Catheters will be&#xD;
      reconstructed on the planning system. Anatomy based inverse planning will be used for dwell&#xD;
      time optimization.&#xD;
&#xD;
      The homogeneity parameters used for optimization aim are:&#xD;
&#xD;
      -For prostate V100 &gt; 95%, V150 &lt;35%, V200 &lt; 6%, where Vn is the fractional volume of the&#xD;
      organ that receives n% of the prescribed dose.&#xD;
&#xD;
      The dose constraints for the organ at risk will be:&#xD;
&#xD;
        -  Urethral dmax &lt; 110% and&#xD;
&#xD;
        -  Rectal 1cc &lt; 60% of prescribed dose.&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
      Feasibility of higher doses administration, toxicity and efficacy will be measured&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by i) urinary retention rate and duration ii) maximum International Prostate Symptom Score and time to normalize</measure>
    <time_frame>12 months</time_frame>
    <description>Data to be collected are:&#xD;
i) urinary retention rate and duration ii) maximum International Prostate Symptom Score and time to normalize</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life measured by alidated instruments including International Prostate Symptom Score and the urinary, bowel and sexual domains of EPIC</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life will be measured through validated instruments including International Prostate Symptom Score and the urinary, bowel and sexual domains of EPIC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity measured by urinary retention rate, International Prostate Symptom Score over time, rectal toxicity and genitourinary toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Data to be collected: urinary retention rate, International Prostate Symptom Score over time, rectal toxicity and genitourinary toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy, measured by PSA</measure>
    <time_frame>24 months</time_frame>
    <description>Patients will be followed with PSA at every follow-up;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction measured with Likert scale question</measure>
    <time_frame>24 months</time_frame>
    <description>Patient Satisfaction will be measured with Likert scale question</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MRI-TRUS fusion guided Single Frac HDR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI-TRUS fusion guided Single Frac HDR</intervention_name>
    <arm_group_label>MRI-TRUS fusion guided Single Frac HDR</arm_group_label>
    <other_name>Single Fraction real time HDR (19Gy)</other_name>
    <other_name>Planning software Oncentra Prostate for Nucletron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men older than 18 years old&#xD;
&#xD;
          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
          -  Clinical stage T1c/T2a disease&#xD;
&#xD;
          -  Low and Intermediate risk disease defined as either Gleason 6 or Gleason 7 and PSA &lt;&#xD;
             20 ng/ml.&#xD;
&#xD;
          -  Prostate volume &lt; 60 cc as determined by ultrasound, CT or MRI&#xD;
&#xD;
          -  Life expectancy of more than 10 years&#xD;
&#xD;
          -  Willing to give informed consent to participate in this clinical trial&#xD;
&#xD;
          -  Able and willing to complete Expanded Prostate Index Composite (EPIC) questionnaire&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) of 0 - 2.&#xD;
&#xD;
          -  Give competent informed consent to participate in this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented nodal or distant metastases&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Previous trans-urethral resection of prostate, previous prostatectomy or HIFU&#xD;
&#xD;
          -  Use of androgen deprivation therapy. Use of 5-alpha-reductase inhibitors is permitted&#xD;
&#xD;
          -  Poor baseline urinary function defined as International Prostate Symptom Score (IPSS)&#xD;
             &gt;19&#xD;
&#xD;
          -  Contra-indication to radical prostate radiotherapy&#xD;
&#xD;
          -  Significant medical co-morbidity rendering patient unsuitable for general anaesthetic&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Gomez-Iturriaga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Cruces/Biocruces</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfonso Gomez-Iturriaga, MD, PhD</last_name>
    <phone>946006233</phone>
    <email>ALFONSO.GOMEZDEITURRIAGAPINA@osakidetza.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Bizkaia</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Gomez-Iturriaga, MD PhD</last_name>
      <phone>+34946006000</phone>
      <phone_ext>6232</phone_ext>
      <email>alfonso.gomezdeiturriaga@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Alfonso Gomez-Iturriaga, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Casquero Ocio, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>January 16, 2015</last_update_submitted>
  <last_update_submitted_qc>January 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Cruces</investigator_affiliation>
    <investigator_full_name>Alfonso Gomez-Iturriaga</investigator_full_name>
    <investigator_title>Staff physician department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>High Dose Rate</keyword>
  <keyword>MRI-TRUS fusion</keyword>
  <keyword>Detection of DILs by MRI</keyword>
  <keyword>SINGLE FRACTION</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

